HemoCue at ADLM in Chicago – Advancing diagnostics with Danaher
From July 27–31, HemoCue will be present at this year’s ADLM conference in Chicago, held in partnership with the Canadian Society of Clinical Chemists (CSCC).
This year, we’re joining forces with our fellow Danaher diagnostics companies to showcase how our collective innovations are accelerating the real-life impact of precision diagnostics. Together with Beckman Coulter, Leica Biosystems, Cepheid and Radiometer, we will welcome customers to our booth to share how our solutions can help you:
Expand Access to Diagnostics
from the largest hospital labs to remote mobile clinics and specialized care units
Future-Proof Healthcare
with diagnostics to help you prepare for what’s next for your lab, your hospital, and your patients
Focus areas for HemoCue
At ADLM, HemoCue will highlight key solutions that support patient care in:
-
- Hemolysis: The HemoCue® Plasma/Low Hb System offers laboratories quantitative plasma-free hemoglobin results within 60 seconds after centrifugation, helping accelerate turnaround times and deliver truly STAT hemolysis assessment.
Visit us here: https://hemocue.com/us/hemocue-plasma-low-system/
- Hemolysis: The HemoCue® Plasma/Low Hb System offers laboratories quantitative plasma-free hemoglobin results within 60 seconds after centrifugation, helping accelerate turnaround times and deliver truly STAT hemolysis assessment.
-
- Nephrology: HemoCue® Hemoglobin Systems provides nephrologists with a fast, simple, and cost-effective way to monitor anemia and manage ESA treatment to support patient safety.
Visit us here: https://hemocue.com/us/nephrology/
- Nephrology: HemoCue® Hemoglobin Systems provides nephrologists with a fast, simple, and cost-effective way to monitor anemia and manage ESA treatment to support patient safety.
-
- Gestational diabetes: The HemoCue® Glucose 201 System is the only CLIA-waived option that offers lab-quality accuracy at the point of care to screen for gestational diabetes—ideal for OBGYN providers.
Visit us here: https://hemocue.com/us/gestational-diabetes/
- Gestational diabetes: The HemoCue® Glucose 201 System is the only CLIA-waived option that offers lab-quality accuracy at the point of care to screen for gestational diabetes—ideal for OBGYN providers.
-
- Ambulatory Surgery Centers (ASCs): The HemoCue® Glucose 201 System supports ASCs by promoting surgical readiness, reducing infection risk, and ensuring regulatory compliance.
Visit us here: https://hemocue.com/us/asc/
- Ambulatory Surgery Centers (ASCs): The HemoCue® Glucose 201 System supports ASCs by promoting surgical readiness, reducing infection risk, and ensuring regulatory compliance.
Don’t miss this opportunity to connect with global leaders in laboratory medicine and explore innovations that are shaping the future of diagnostics.
Find us at Booth #2803
Learn more about ADLM here: https://meeting.myadlm.org/
Book your appointment with HemoCue below
